Tumor-associated epitope peptide and application thereof
The vaccine prepared by using tumor-associated epitope peptides derived from embryonic stem cells, combined with adjuvant, significantly inhibits bladder cancer growth and induces strong T cell responses in a mouse model, solving the insufficient immunogenicity and immunity of existing tumor vaccines. The problem of escape has achieved personalized tumor treatment effects.
Patent Information
- Application Number
- CN202310534458.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-12
AI Technical Summary
The existing tumor vaccines are weak in the treatment of bladder cancer, and the immune escape of tumor cells leads to poor treatment effects, which cannot meet the needs of individualized diagnosis and treatment.
Using tumor-related antigen epitope peptides derived from embryonic stem cells, including CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, NUF-2, etc. The vaccines prepared through these antigen epitope peptides can effectively inhibit tumors. Cell growth or stimulation of T cell responses, combined with adjuvants such as CpG oligodeoxynucleotides to enhance anti-tumor effects.
In a mouse model, it significantly inhibits bladder cancer growth and induces specific T cell responses with high levels of IFN-γ secretion, which improves tumor suppression effect and provides a safe and highly specific personalized treatment plan.
Smart Images

Figure CN118930633A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to tumor-related antigen epitope peptides and applications thereof. Background Art
[0002] According to the latest statistics from IARC, the International Agency for Research on Cancer under the World Health Organization, bladder cancer ranks as the tenth most common type of cancer in the world. Every year, about 600,000 people are diagnosed with bladder cancer worldwide, and more than 200,000 die from the disease. Bladder cancer is one of the most challenging cancers to diagnose and treat. Its diagnosis mainly relies on cystoscopy, which is an invasive and costly method. At present, traditional treatments for cancer include surgery, radiotherapy, and chemotherapy. Although traditional treatments can effectively cure cancer, they are very destructive to the immune system and cannot meet the needs of individualized diagnosis and treatment. Emerging immunotherapies represented by vaccines, monoclonal antibodies, and adoptive T cell therapy have made great progress in the past few decades, which have made up for the shortcomings of traditional therapies. A large number of studies have entered the clinical trial evaluation stage, and single or combined regimens can provide patients with more effective solutions.
[0003] Unlike traditional preventive vaccines that stimulate the body to produce immune responses with exogenous antigens, cancer vaccines can target endogenous intracellular antigens and may trigger new tumor-specific immune responses, thereby exerting a therapeutic effect. The emergence of therapeutic cancer vaccines dates back to the early 20th century, when killed streptococci and Serratia were used to treat malignant tumors. Today, cancer vaccines have become a promising candidate therapeutic strategy for solid tumor immunotherapy, which stimulates antitumor immunity through tumor antigens delivered in the form of whole cells, peptides, nucleic acids, etc. Tumor antigens are divided into tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). The difference is that the former is an antigen that is only expressed in tumor cells but not in normal cells, while the latter exists in both tumor cells and normal cells, but is highly expressed in tumor cells. Cancer vaccines are divided into two categories, predefined antigens and anonymous antigens, depending on whether the antigen is defined before treatment. Predefined antigens are further subdivided into personalized and shared categories based on the frequency of expression of the antigen in patients with the same tumor type. Shared vaccines are widely used in a wide range of patient groups and can be evaluated by standard detection methods (cytology, immunohistochemistry, flow cytometry, etc.), so they can target both TSAs and TAAs. Cancer vaccines work mainly through the recognition and uptake of tumor antigens by antigen-presenting cells (APCs), which are presented to CD8+T cells (also known as cytotoxic T lymphocytes) through HLA-1. Subsequently, CD8+T cells secrete a variety of cytokines (such as IFN-γ) to induce the body's immune response and kill tumors. In summary, due to the weak immunogenicity of current tumor vaccines, the immune escape of tumor cells leads to poor tumor vaccine effects, resulting in poor tumor suppression effects. Summary of the invention
[0004] Based on this, it is necessary to provide a tumor-associated antigen epitope peptide that can be used to prepare a tumor-associated antigen epitope peptide that can inhibit tumor cell growth or stimulate tumor cells to produce T cell response and its application.
[0005] A tumor-associated antigen epitope peptide, wherein the tumor-associated antigen epitope peptide is derived from embryonic stem cells, and the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
[0006] The study found that among at least one of the embryonic stem cell-derived tumor-associated antigens selected from CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the tumor-associated antigens KIF4A and NUF-2 expressed by ESCs can effectively inhibit the growth of bladder cancer, and the tumor-associated antigens CENPM, NUF-2, and IQGA3 expressed by ESCs can strongly stimulate the immune response of specific T cells, which is manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, exerting a certain therapeutic effect, and can be used to prepare drugs that inhibit tumor cell growth or stimulate tumor cells to produce T cell responses. After in vivo experiments, the vaccine has an inhibitory effect on bladder cancer in mice.
[0007] In some embodiments, the tumor-associated antigen epitope peptide contains an amino acid sequence such as one of the peptide segments shown in SEQ ID No. 1-SEQ ID No. 10.
[0008] In some embodiments, the tumor-associated antigen epitope peptide contains an amino acid sequence such as one of the peptide segments shown in SEQ ID No.11-SEQ ID No.20.
[0009] The use of the above tumor-associated antigen epitope peptide in the preparation of drugs for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell response.
[0010] In some embodiments, the tumor comprises at least one of bladder cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, and uterine cancer.
[0011] A drug for treating tumor-related diseases, comprising: at least one of the above-mentioned tumor-related antigen epitope peptides.
[0012] In some embodiments, in the drug for treating tumors, the tumor-associated antigen epitope peptide contains a peptide segment with an amino acid sequence as shown in SEQ ID No. 10 or a peptide segment with an amino acid sequence as shown in SEQ ID No. 20.
[0013] In some embodiments, in the drug for treating tumors, the tumor-associated antigen epitope peptide contains a first peptide segment and a second peptide segment, the first peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.9 and the amino acid sequence shown in SEQ ID No.19, and the second peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.8 and the amino acid sequence shown in SEQ ID No.18.
[0014] In some of the embodiments, an adjuvant is further included, wherein the adjuvant includes at least one of CpG oligodeoxynucleotide and Poly IC.
[0015] In some of the embodiments, a pharmaceutically acceptable carrier and / or excipient is also included.
[0016] The use of antigen epitope peptides derived from embryonic stem cells in the preparation of drugs for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses, wherein the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The experimental operation flow chart of Example 1;
[0018] Figure 2 The results of the tumor growth inhibition test of antigen epitope peptides derived from various genes in the experiment are shown in FIG.
[0019] Figure 3 This is a graph showing the results of the test of the inhibitory effect of the mixed peptide vaccine of effective antigen epitope peptides on tumor growth in Example 1;
[0020] Figure 4 This is a graph showing the test results of the mixed peptide segments’ effects on immune cells in the blood;
[0021] Figure 5 This is a graph showing the results of testing the ability of specific T cells to secrete IFN-γ induced by tumor antigen epitope peptides. DETAILED DESCRIPTION
[0022] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation of the present invention is described in detail below in conjunction with specific embodiments and drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention, so the present invention is not limited by the specific implementation disclosed below.
[0023] The present application provides a tumor-associated antigen epitope peptide, which is derived from embryonic stem cells, wherein the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
[0024] The potential of stem cell vaccines for cancer treatment comes from early observations that embryonic / fetal tissue immunity leads to rejection of transplanted tumors in animals. Subsequent studies have further confirmed that inoculation of embryonic materials in animals can induce cellular and humoral immunity against transplantable tumors and carcinogen-induced tumors. The similarity of tumor cell and embryonic cell antigens (i.e., shared antigens) is the basis for their hypothetical use as vaccines for cancer treatment. After continuous inoculation of hepatic stem cells (HSC) or embryonic stem cells (ESC) for 3 weeks, hepatoma cells Hepa1-6 were subcutaneously inoculated 1 week (group 1) and 4 weeks (group 2) after inoculation. In the experimental group, mice immunized with HSC vaccine did not form tumors within one week, and only 10% of mice immunized with ESC vaccine formed tumors. However, the tumor formation rate of mice in the control group reached 60%, and the situation of (group 2) when detecting long-term memory response was roughly the same as (group 1). Experiments conducted in the same period showed that in a subcutaneous liver cancer mouse model, 80% of mice that received HSC vaccination had completely eliminated tumor burden, but 40% of mice that received ESC vaccination had tumors that did not grow over time. The data supported the excellent performance of stem cells as preventive or therapeutic cancer vaccines. However, there may be certain limitations in the development of embryonic / fetal materials into vaccines for clinical use, such as ethical aspects, tumorigenicity, and alloimmunity. Autologous iPSC (Induced Pluripotent Stem Cell, iPSC) can also be used directly as a vaccine after irradiation. Its emergence is overcoming the above limitations. It is worth noting that single iPSC immunity does not exert a strong anti-tumor effect, and the combined use of CpG as an adjuvant solves this problem. The anti-cancer effect has been verified in breast cancer, melanoma, and mesothelioma.
[0025] Centromere protein M (CENPM) is encoded by the gene CENPM, which is involved in kinetochore protein assembly and chromosome segregation, and plays an important role in the cell cycle. Recent research progress has focused on the association between this protein and cancer occurrence. CENPM promotes tumorigenesis through multiple pathways such as p53 and mTOR / p70S6k. Kinetochore protein (NUF2) is encoded by NUF2, is associated with centromeres, and is involved in chromosome segregation. Similarly, upregulation of NUF2 also promotes tumorigenesis, and changes in NUF2 levels have an impact on cell proliferation, migration, and invasion. The chromosome-associated molecular motor (KIF4A), a member of the kinesin superfamily, is encoded by KIF4A, which is involved in intracellular transport and is responsible for the maintenance of cell physiological morphology. In addition, it is also involved in chromosome aggregation and segregation during mitosis. Similarly, changes in KIF4A levels are also associated with tumor development. In summary, they have the potential to be used as predictive markers for cancer prognosis, however, there are relatively few reports on them as antigenic peptides.
[0026] The study found that among at least one of the embryonic stem cell-derived tumor-associated antigens selected from CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the tumor-associated antigens KIF4A and NUF-2 expressed by ESCs can effectively inhibit the growth of bladder cancer, and the tumor-associated antigens CENPM, NUF-2, and IQGA3 expressed by ESCs can strongly stimulate the immune response of specific T cells, which is manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, exerting a certain therapeutic effect, and can be used to prepare drugs that inhibit tumor cell growth or stimulate tumor cells to produce T cell responses. After in vivo experiments, the vaccine has an inhibitory effect on bladder cancer in mice.
[0027] In some embodiments, the tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences as shown in SEQ ID No. 1-SEQ ID No. 10.
[0028] In some embodiments, the tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences as shown in SEQ ID No.11-SEQ ID No.20. The peptide segments with amino acid sequences as shown in SEQ ID No.11-SEQ ID No.20 are extended peptides of the peptide segments with amino acid sequences as shown in SEQ ID No.1-SEQ ID No.10, and the two are basically the same in function. Because a shearing process is required when dendritic cells present antigen epitopes, an extended peptide containing the peptide segments with amino acid sequences as shown in SEQ ID No.1-SEQ ID No.10 is synthesized during actual synthesis.
[0029] One embodiment of the present study also provides a drug for treating tumors, comprising: at least one of the above-mentioned tumor-associated antigen epitope peptides.
[0030] Traditional methods, such as surgery, radiotherapy and chemotherapy, are invasive and have good effects on non-spreading tumors in the early stage, but they cause indiscriminate and irreversible damage to the human body and the human immune system, increasing the risk of infection with other diseases. Immune checkpoint inhibitors have improved the prognosis of people who are intolerant to chemotherapy, but they face the problem of low overall response rate of patients in clinical applications and the risk of inducing fatal immune-related side effects. Adoptive T cell therapy (such as Chimeric Antigen Receptor T-Cell, CAR-T) can quickly induce the body's immune response while bringing strong toxicity. In addition, the time cost and high cost of transformation and re-infusion, as well as off-target and antigen escape also limit the use of this technology. Cancer vaccines have the advantages of high safety and few side effects due to their clear mechanism of action and known antigen targets. The present invention aims to expand the preparation process of stem cell-based cancer vaccine epitope identification and system, and accelerate the construction of vaccine discovery platform.
[0031] The study found that among at least one of the embryonic stem cell-derived tumor-associated antigens selected from CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the tumor-associated antigens KIF4A and NUF-2 expressed by ESCs can effectively inhibit the growth of bladder cancer, and the tumor-associated antigens CENPM, NUF-2, and IQGA3 expressed by ESCs can strongly stimulate the immune response of specific T cells, which is manifested as stimulating peptide-specific CTL to secrete high levels of IFN-γ and inhibit tumor growth, and play a certain therapeutic role. The drugs for treating tumors prepared from the above tumor-associated antigen epitope peptides can inhibit tumor cell growth or stimulate tumor cells to produce T cell responses. After in vivo experiments, the vaccine has an inhibitory effect on bladder cancer in mice.
[0032] In some embodiments, the tumor comprises at least one of bladder cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, and uterine cancer.
[0033] In some embodiments, in the drug for treating tumors, the tumor-associated antigen epitope peptide contains a peptide segment with an amino acid sequence such as SEQ ID No. 10 or a peptide segment with an amino acid sequence such as SEQ ID No. 20. It has been verified by experiments that the tumor-associated antigen epitope peptide in the drug can induce a stronger T cell response and a more significant tumor inhibition effect, and can be used as an anti-tumor drug.
[0034] In some embodiments, in the drug for treating tumors, the tumor-associated antigen epitope peptide contains a first peptide segment and a second peptide segment, the first peptide segment contains at least one of the amino acid sequence shown in SEQ ID No. 9 and the amino acid sequence shown in SEQ ID No. 19, and the second peptide segment contains at least one of the amino acid sequence shown in SEQ ID No. 8 and the amino acid sequence shown in SEQ ID No. 18. According to experimental verification, the tumor-associated antigen epitope peptide in the drug has a more significant tumor inhibitory effect.
[0035] In some embodiments, the drug for treating tumors further comprises an adjuvant, and the adjuvant comprises at least one of CpG oligodeoxynucleotide and Poly IC. With the assistance of the above adjuvant, the anti-tumor effect of the tumor-associated antigen epitope peptide or the effectiveness of treating tumors can be improved. Wherein, the tumor can be bladder cancer.
[0036] In some embodiments, the drug for treating tumor-related diseases further comprises a pharmaceutically acceptable carrier and / or adjuvant. The pharmaceutically acceptable carrier and / or adjuvant, for example, comprises a solvent, and the solvent, for example, may be DPBS. It should be noted that the pharmaceutically acceptable carrier and / or adjuvant mentioned above are not limited thereto, and the corresponding pharmaceutically acceptable carrier and / or adjuvant may be selected as required.
[0037] In some embodiments, the drug for treating tumors is a vaccine.
[0038] Among the above-mentioned drugs for treating tumors, vaccines prepared from tumor-associated antigens KIF4A-1, KIF4A-2, and NUF-2 expressed by ESCs can effectively inhibit the growth of bladder cancer. CENPM and NUF-2 can strongly stimulate the immune response of specific T cells, which is manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, thus playing a certain therapeutic role.
[0039] Furthermore, among the above-mentioned drugs for treating tumors, the single peptides CENPM, NUF-2, KIF4A-1, and KIF4A-2 with anti-cancer effects were configured into peptides and used as vaccines to immunize mice, and the combination showed good anti-cancer effects. In addition, the selected peptides were used in combination with the adjuvant CpG oligodeoxynucleotide (CPG-ODN), which was effective in treating bladder cancer. The peptides derived from embryonic stem cells can be used in the preparation of tumor therapeutic peptide vaccines.
[0040] The present application provides several tumor-associated antigens (TAAs) expressed by embryonic stem cells (ESCs) as potential therapeutic TAAs and effective epitopes, which can be used to prepare a shared vaccine that effectively inhibits the growth of bladder cancer, has high safety, few toxic side effects, and high specificity.
[0041] The following is the specific embodiment section.
[0042] Unless otherwise specified, the reagents and instruments used in the examples are all conventionally selected in the art. The experimental methods without specific conditions in the examples are usually carried out according to conventional conditions, such as the conditions described in the literature, books, or the methods recommended by the kit manufacturer. The reagents used in the examples are all commercially available.
[0043] In the following examples, unless otherwise specified, the protein and epitope peptide sequences screened in Example 1 are shown in Table 1.
[0044] Table 1 Proteins and epitope peptide sequences screened in Example 1
[0045]
[0046] In Table 1, the extended peptide contains the epitope peptide sequence and is functionally the same as the epitope peptide. Because dendritic cells require a cleavage process when presenting antigen epitopes, an extended peptide containing the epitope peptide is actually synthesized; population coverage refers to the proportion of people in the population who have at least one HLA allele that can bind to the peptide segment.
[0047] Example 1
[0048] The main contents of this example are: using predictive immunoinformatics algorithms to predict shared genes that are highly expressed in ESCs and tumor cells but very low in normal tissues, predicting antigen epitope peptides of CD8+T cells that highly express these genes, selecting CENPM, KIF4A-1, KIF4A-2, and NUF-2 as potential therapeutic TAAs and effective epitopes. Designing vaccines based on these antigens, CENPM, KIF4A-1, KIF4A-2, and NUF-2, verifying the sustained tumor growth inhibition effect of these antigens in a bladder cancer mouse model, and evaluating the immune response of antigen-specific T cells by enzyme-linked immunospot assay (ELISPOT).
[0049] like Figure 1 As shown ( Figure 1 , the specific operation process of this embodiment is as follows:
[0050] (1) Screening of therapeutic TAAs and effective epitopes:
[0051] By performing RNA-seq sequencing on ESC (129) cell lines, bladder cancer cell lines (MB49), liver cancer cell lines (ML-1), and lung cancer cell lines (LLC), the expressed genes were compared with the cancer cell line MB49 and healthy tissues to screen shared genes that are highly expressed in ESCs but very lowly expressed in normal tissues as potential therapeutic TAAs.
[0052] By sequencing and analyzing the transcriptomes of mouse tumor cells and embryonic stem cells, we obtained genes that are highly expressed in both tumor cells and embryonic stem cells, numbered 1-10. After literature research and in vitro experimental verification, we screened out effective genes, including Pep-1 (cenpm), Pep-8 (kif-4a-1), Pep-9 (kif-4a-2), and Pep-10 (nuf-2). We also obtained the antigenic epitopes of these genes through analysis, and cooperated with Gill Biochemical (Shanghai) Co., Ltd. to synthesize extended peptides containing the antigenic epitope peptides of these genes.
[0053] (2) Preparation of tumor vaccines and evaluation of their therapeutic potential:
[0054] Cancer cells and animal models: MB49 bladder cancer cells were grown in DMEM containing 10% FBS (Fetal Bovine Serum, Gibco, 10099141C) and 1% PS (Penicillin-Streptomycin-Glutamine, Gibco, 10378016). 5 MB49 cancer cells were resuspended in 100 μL DPBS and injected subcutaneously into the lower back of male C57BL / 6 mice (6-8 weeks old) to construct a mouse bladder cancer treatment model. After the first tumor inoculation, the mice developed tumors in about 5 days. After tumor formation, the tumor growth was monitored every 3 days. The long diameter (a) and short diameter (b) of the tumor were measured with a vernier caliper. According to the solid tumor volume V = a×b×b / 2, the volume of each solid tumor was calculated and the tumor growth curve was drawn.
[0055] Vaccine preparation and periodic vaccination: Tumor-bearing mice were randomly divided into: DPBS group, CpG group, CpG+CENPM group, CpG+IQGA3-1+IQGA3-2 group, CpG+KIF4A-1+KIF4A-2 group, CpG+NUF-2 group, 6 mice in each group. DPBS (phosphate buffered saline) was used as solvent and CpG ODN 1826 was used as vaccine adjuvant. Vaccines were prepared according to the groups. The final concentration of CpG ODN 1826 was 10 μM, and the final concentration of each peptide was 100 μg / 100 μL. DPBS was used to make the volume to 100 μL and injected into the subcutaneous part of the back of the neck of the mouse. The first vaccination was carried out on Day 3, and the same vaccine was vaccinated every 3 days thereafter, for a total of 7 times.
[0056] Preparation of spleen single cell suspension: The spleen was crushed and collected into a 15 mL centrifuge tube through a 70 μm cell sieve. The red blood cells were lysed with 1 mL of lysate to stop the lysis. The cells were then washed with DPBS and the cell count was used for ELISPOT.
[0057] Isolation of tumor infiltrating lymphocytes (TIL): On Day 26, mice were anesthetized and killed, and solid tumors were removed. The tumor was minced and suspended in 5 mL of digestion solution (50 mL of HBSS containing 2 mg / mL Collagenase A and 50 units / mL DNaseⅠ), and incubated in a water bath at 37°C, 180 rpm for 20 min. The digested tumor fragments were collected into a 50 mL centrifuge tube through a 100 μm cell sieve, and the digestion was terminated with a wash buffer containing EDTA. The cells were separated by centrifugation at 400 g for 25 min using 40% and 80% percoll, and the middle layer lymphocytes were collected, then the cells were washed with DPBS, and the cell count was used for ELISPOT.
[0058] ELISPOT analysis: Splenocytes were isolated as described above and 5×10 5 The cells were co-cultured with different peptides (10 μg) for 20 h. The size and number of IFN-γ positive spots were calculated using Adobe Photoshop CS6 software.
[0059] Data analysis: Data were analyzed using GraphPad Prism, and all values in bar graphs and curves are expressed as mean ± SEM. Differences between groups were evaluated using ordinary one-way ANOVA or Unpaired t test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0060] The experimental results are as follows Figures 2 to 5 shown.
[0061] Figure 2 This is a graph showing the results of tumor growth inhibition tests using antigen epitope peptides derived from various genes in the experiment. Figure 2 All mice were injected subcutaneously with 3×10 5 MB49 bladder cancer cells were immunized with peptides on days 3, 6, 9, 12, 15, 18, and 21, and the mice were euthanized on day 26. Each mouse in the experimental group was subcutaneously injected with a synthetic epitope peptide plus an adjuvant, CpG, with a total injection volume of 100 μl per mouse, and the amount of CpG was 10 μM. The size of the mouse tumor was detected every 3 days after the peptide immunization. Figure 2 It can be seen that after immunization with different peptides, the tumor size of mice in the KIF4A-1 / -2 group and the NUF-2 group was significantly inhibited, CENPM had a partial tumor growth inhibitory effect, and the inhibitory effect of other groups of vaccines on bladder cancer was not obvious.
[0062] Figure 3The above-mentioned effective antigen epitope peptides were mixed to prepare a vaccine, and the mixed peptide vaccine was tested for its inhibitory effect on tumor growth. Figure 3 All mice were injected subcutaneously with 3×10 5 MB49 bladder cancer cells were immunized with peptides on days 3, 6, 9, 12, 15, 18, and 21, and the mice were euthanized on day 26. Each mouse in the experimental group was subcutaneously injected with a synthetic epitope peptide plus adjuvant CpG. The vaccine peptides contained KIF4A-1 / -2, NUF-2, and CENPM dissolved in 100 μL DPBS, containing 10 μM adjuvant CpG. The total amount of each injection was 100 μL. The peptides were immunized for 3 days, and the tumor size of the mice was detected every 3 days. Figure 3 It can be seen that after immunization with different peptides, the mixed peptide group has a significant tumor growth inhibitory effect.
[0063] Figure 4 This is a graph showing the test results of the effect of mixed peptides on immune cells in the blood. Figure 4 All mice were injected subcutaneously with 3×10 5 MB49 bladder cancer cells were immunized with mixed peptides + adjuvant on days 3, 6, 9, 12, 15, 18, and 21, and mice were euthanized on day 26. Peripheral blood was collected when mice were sacrificed, and CD45, CD4, CD44, CD25, and FOXP3 flow cytometry antibodies were added to 100 μL of blood for flow cytometry multicolor staining to analyze the changes in the proportion of CD4 memory cells and Treg cells in the blood. Figure 4 It can be seen that after mixed peptide immunization, the proportion of memory T cells was significantly increased, while Treg was significantly inhibited.
[0064] Figure 5 This is a graph showing the results of testing the ability of specific T cells to secrete IFN-γ induced by tumor antigen epitope peptides. Figure 5 In the experiment, the mice were euthanized, the spleen tissue was removed aseptically, and after grinding, the monocytes were separated using lymphocyte separation fluid. The monocytes were incubated in the wells of the ELISPOT plate and stimulated simultaneously. The cells were cultured and captured by cytokines at 37°C. The formation of spots was detected after 20 hours, and the number of T cells that specifically secreted IFN-γ in the spleen cells of the immunized mice could be detected. Figure 5 It can be seen that mice immunized with epitope peptides can induce T cell immune responses related to IFN-γ.
[0065] Combined with the above figures, the vaccine has an inhibitory effect on bladder cancer in mice after in vivo experiments. In the mouse bladder cancer model, the vaccine treatment was started every 3 days on the 3rd day after tumor inoculation, for a total of 7 times. Figure 1) It can be seen that compared with the control DPBS group and CpG group, the vaccines containing peptides alleviated tumor growth to varying degrees. With the assistance of CpG, the combined vaccine of KIF4A-1+KIF4A-2 and the NUF-2 vaccine significantly inhibited the growth of bladder cancer tumors. However, CENPM and the combined IQGA3-1+IQGA3-2 vaccine did not show obvious tumor inhibition. IFN-γ ELISPOT analysis was performed on mouse spleen cells. The results showed that compared with the control DPBS group and CpG group, the peptide CENPM and the peptide NUF-2 could stimulate spleen cells to produce significant T cell responses.
[0066] In summary, the vaccine NUF-2 can induce the strongest T cell response and the most significant tumor inhibition effect, proving its potential as a tumor vaccine. It is worth noting that CENPM can induce T cell response but does not show strong anti-tumor effect; while the KIF4A-1+KIF4A-2 combined vaccine, which can effectively inhibit tumor growth, did not induce a strong T cell response under the stimulation of the peptide segments separately, suggesting that multi-antigen vaccines are more effective than single-antigen vaccines in inhibiting cancer development.
[0067] In this application, multiple genes co-expressed by tumor cells and stem cells were screened, and epitope peptides and extended peptides expressed by these genes were predicted and analyzed. These peptides were synthesized in vitro, and these peptides can effectively inhibit the growth of bladder cancer tumors and activate strong T cell-related specific immune responses. Animal experiments have shown that these ESC-derived antigen epitope peptides have a good immunotherapy effect on bladder cancer.
[0068] This application combines animal experiments to verify the reliability of potential tumor-associated antigens TAAs and epitopes previously predicted by bioinformatics algorithms based on the anti-tumor effects of ESCs as vaccines for the treatment of bladder cancer. The scheme provides a complete set of processes, from the initial screening of tumor-specific antigens, the preparation and vaccination of epitope peptide vaccines, and subsequent immunological experimental analysis to test their effectiveness. In addition, the scheme configures the individual peptide segments CENPM, NUF-2, KIF4A-1, and KIF4A-2 that have been previously obtained and pre-experimentally verified to have anti-cancer effects into polypeptides, and uses them as vaccines to immunize mice, and the combination shows good anti-cancer effects. The disclosed technical route is easy to reproduce, shortens the cycle of discovery and verification, and greatly enhances the application potential of stem cell-based gene epitope vaccines as therapeutic tumor vaccines in the context of precision medicine.
[0069] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A tumor-associated antigen epitope peptide, characterized in that: The tumor-associated antigen epitope peptide is derived from embryonic stem cells, and the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
2. The tumor-associated antigen epitope peptide according to claim 1, characterized in that: The tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences as shown in SEQ ID No.1-SEQ ID No.
10.
3. The tumor-associated antigen epitope peptide according to any one of claims 1 to 2, characterized in that: The tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences as shown in SEQ ID No.11-SEQ ID No.
20.
4. Use of the tumor-associated antigen epitope peptide according to any one of claims 1 to 3 in the preparation of a drug for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses.
5. The use according to claim 4, characterized in that: The tumor includes at least one of bladder cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, and uterine cancer.
6. A drug for treating tumors, characterized in that: include: At least one of the tumor-associated antigen epitope peptides according to any one of claims 1 to 3.
7. The drug for treating tumors according to claim 6, characterized in that: In the drug for treating tumors, the tumor-associated antigen epitope peptide contains a peptide segment with an amino acid sequence as shown in SEQ ID No. 10 or a peptide segment with an amino acid sequence as shown in SEQ ID No. 20; Alternatively, in the drug for treating tumor-related diseases, the tumor-associated antigen epitope peptide contains a first peptide segment and a second peptide segment, the first peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.9 and the amino acid sequence shown in SEQ ID No.19, and the second peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.8 and the amino acid sequence shown in SEQ ID No.
18.
8. The drug for treating tumors according to claim 6, characterized in that: Also included is an adjuvant, which includes at least one of CpG oligodeoxynucleotide and Poly IC.
9. The drug for treating tumors according to any one of claims 6 to 8, characterized in that: Also included are pharmaceutically acceptable carriers and / or excipients.
10. Use of antigen epitope peptides derived from embryonic stem cells in the preparation of drugs for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses, characterized in that: The tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
